# SLE Digital Twin Living Requirements Specification (SLE-DT LRS)

## Revision Status

### Integrated Literature Reviews
1. SLE DEG Bioinformatics Review.
2. AI, Biomarkers, and Precision Rheumatology Review.
3. Digital Twins and the Metaverse in Healthcare Review.
4. AI Autoimmune Research Trends (2025 Bibliometric Analysis).
5. AI for Systemic Lupus Erythematosus Personalized Treatment.
6. The Role of Health Information Technology in the Control and Management of SLE.
7. Federated Learning Security and Governance in Healthcare.

### Current Revision Purpose
This revision merges the Federated Learning, privacy, security, and governance review into the existing SLE-DT Living Requirements Specification. The review strengthens governance, privacy, security, stakeholder, validation, and future scaling requirements but does **not** change the current MVP scope.

---

## 1. Canonical Thesis Direction

### 1.1 Selected MVP Architecture
**Transcriptomics-First + Molecular-Endotype-Aware Healthcare Digital Twin**

### 1.2 MVP Scope Decision
The MVP remains focused on:
- Systemic Lupus Erythematosus (SLE).
- Transcriptomic data.
- Healthy-vs-disease immune-state modeling.
- Molecular endotype discovery.
- Immune-tolerance restoration.
- Explainable pathway and target prioritization.
- Research-only, non-clinical deployment.

The integrated literature continues to support molecular endotyping as the preferred MVP strategy because SLE heterogeneity is a primary modeling challenge and patient grouping/stratification is essential.

### 1.3 Research Objective Representation
The Digital Twin represents:
- Patient immune state.
- Disease-state deviation from health.
- Molecular endotypes.
- Active pathways.
- Candidate restoration opportunities.
- Patient-specific biological hypotheses.

It does **not** represent:
- A treatment recommendation engine.
- A clinical decision support product.
- A telemedicine platform.
- A patient-management application.
- A production federated-learning system.
- A regulatory-grade medical device.

---

## 2. Executive Thesis Objective
Develop an explainable Digital Twin that models patient-specific immune dysregulation, identifies disease-driving pathways, stratifies patients into biologically meaningful subgroups, simulates restoration of immune tolerance, and generates testable therapeutic hypotheses.

---

## 3. MVP Requirements

### 3.1 Included in MVP
- Public GEO datasets.
- Healthy control cohorts.
- Differential expression analysis.
- Pathway enrichment analysis.
- Protein-protein interaction (PPI) analysis.
- Molecular endotype discovery.
- Healthy reference twin.
- Patient twin.
- Twin comparison engine.
- Virtual perturbation engine.
- Explainable target ranking.
- Technical validation.
- Biological validation.
- Basic public-data governance documentation.

### 3.2 Explicitly Out of Scope for MVP
- Clinical deployment.
- Treatment recommendation.
- Real-time monitoring.
- Telemedicine implementation.
- Wearable integration.
- Multi-omics integration.
- EHR integration.
- Production federated learning.
- Processing protected health information.
- Regulatory approval.

### 3.3 MVP Feasibility Rationale
The MVP remains feasible because it relies on public transcriptomic datasets and avoids protected clinical data, multi-institutional deployment, real-time monitoring, and regulated clinical use. The Federated Learning review supports future privacy-preserving collaboration but does not justify adding FL to the initial MVP.

---

## 4. SLE Heterogeneity Requirements
The Health IT review reinforces that SLE presents with highly variable manifestations and disease trajectories.

### Requirements
- The architecture must assume patient heterogeneity.
- Patient grouping must be performed prior to major downstream analyses whenever feasible.
- Disease modeling should not assume a single dominant disease mechanism across all patients.
- Validation should assess whether prioritized pathways remain stable within identified endotypes.
- Future clinical expansions should be capable of integrating organ involvement, symptom clusters, disease severity, treatment history, and patient-reported outcomes.

---

## 5. Molecular Endotype Requirements
Disease subtyping is a foundational requirement.

### 5.1 Required MVP Signals
- Gene-expression signatures.
- Pathway activation profiles.
- Interferon activity.
- Immune-state signatures.
- B-cell-related signatures.

### 5.2 Future Endotype Layers
Potential future grouping strategies identified across reviewed literature:
- Biological markers.
- Organ involvement.
- Disease severity.
- Symptom clusters.
- Treatment-response patterns.
- Longitudinal clinical trajectories.

### 5.3 Current MVP Decision
Biological and transcriptomic stratification remains the preferred MVP approach because it is directly supported by available data and aligns with the thesis goal of molecular-endotype-aware immune-state modeling.

---

## 6. Scientific Foundation

### 6.1 Core Biological Themes
- Immune tolerance restoration.
- Molecular heterogeneity.
- Patient stratification.
- Explainable AI.
- Transcriptomic disease-state modeling.

### 6.2 Key Disease Mechanism Categories
- Neutrophil biology.
- Interferon biology.
- B-cell biology.
- T-cell regulatory biology.

### 6.3 Priority Hub Genes
The following hub genes remain priority monitoring targets from prior DEG/PPI literature integration:
- CCNB2
- CDCA8
- AURKB
- BUB1B
- RRM2
- BIRC5
- UBE2C

---

## 7. Data Strategy

### 7.1 Core Datasets
- GSE162828.
- GSE169080.

### 7.2 First-Class Requirement: Healthy Controls
Healthy-control cohorts are critical for meaningful disease-state comparison and must remain a first-class requirement.

### 7.3 Dataset Documentation Requirements
Capture when available:
- Age.
- Sex.
- Ethnicity/ancestry.
- Disease subtype.
- Organ involvement.
- Clinical metadata.
- Treatment history.
- Cohort provenance.
- Dataset source and access conditions.

### 7.4 Data Standardization Requirements
Because SLE data may originate from multiple specialties and diagnostic modalities:
- Data normalization shall be documented.
- Batch-effect correction shall be documented.
- Missing-data handling shall be documented.
- Feature provenance shall be documented.
- Dataset inclusion/exclusion criteria shall be documented.

### 7.5 Governance Impact of Current MVP Data Choice
Because the MVP uses public datasets only and does not process protected health information, the immediate privacy risk is lower than in clinical or multi-institutional deployment. However, data provenance, dataset usage restrictions, reproducibility, and ethical documentation still remain required.

---

## 8. Clinical Context Layer
The Health IT review highlights that SLE management often involves multiple specialties:
- Rheumatology.
- Nephrology.
- Dermatology.
- Neurology.
- Hematology.

Future Digital Twin evolution should support incorporation of disease information from multiple clinical domains. This remains outside the MVP.

---

## 9. Digital Twin Functional Architecture

### 9.1 MVP Functional Components
1. Data ingestion module.
2. Quality-control and normalization module.
3. Differential gene expression engine.
4. Pathway enrichment/scoring engine.
5. PPI/network analysis engine.
6. Molecular endotype discovery engine.
7. Healthy reference twin constructor.
8. Patient twin constructor.
9. Twin comparison engine.
10. Virtual perturbation engine.
11. Explainability engine.
12. Target ranking engine.
13. Technical validation module.
14. Biological validation module.
15. Governance documentation module.

### 9.2 Design Constraint
No universally optimal Digital Twin architecture has been established across the reviewed literature. Therefore, the SLE-DT architecture must remain application-driven and justified by the thesis objective: transcriptomics-first immune-state modeling and immune-tolerance restoration.

---

## 10. Security, Privacy, and Governance Requirements

### 10.1 Requirement Status
Security, privacy, compliance, and governance are elevated to first-class requirements. They shall not be treated as post-development add-ons.

### 10.2 Applicability to MVP
The MVP uses public datasets and does not access protected health information. Therefore:
- Full clinical compliance workflows are not required for the MVP.
- Production federated learning is not required for the MVP.
- Formal protected-data access workflows are not required for the MVP.

However, the MVP should still include:
- Dataset provenance documentation.
- Dataset usage documentation.
- Reproducibility documentation.
- Code and model traceability.
- Clear statement that outputs are research hypotheses, not clinical recommendations.

### 10.3 Governance Principles
Future system evolution shall follow:
- Privacy-by-design.
- Security-by-design.
- Explainability-by-design.
- Validation-by-design.
- Human oversight.
- Documentation-first model development.

### 10.4 Privacy Requirements
For the MVP:
- Use public data only.
- Do not process protected health information.
- Track dataset provenance.
- Document usage constraints.

For future clinical or institutional deployments:
- Define data access controls.
- Document lawful/approved data use.
- Evaluate privacy leakage risks.
- Define stakeholder approval workflows.
- Perform privacy impact assessment before sensitive-data access.

### 10.5 Security Requirements
Future architectures should support:
- Secure communications.
- Encryption for data/model transfer.
- Role-based access control.
- Audit logging.
- Threat modeling.
- Security monitoring.
- Incident response planning.

### 10.6 AI Governance Requirements
Future AI-enabled Digital Twin extensions should support:
- Human approval workflows.
- Decision traceability.
- Model and agent audit logs.
- Security review before sensitive-data access.
- Privacy review before sensitive-data access.
- Governance review before deployment.
- Documentation of model limitations and intended use.

---

## 11. Federated Learning Roadmap

### 11.1 Status
Federated Learning is a **future architecture option**, not an MVP requirement.

### 11.2 Potential Benefits for Future SLE-DT
Federated Learning may support:
- Multi-institution collaboration.
- Larger patient populations.
- More diverse cohorts.
- Reduced need for centralized patient-data storage.
- Privacy-preserving model development across hospitals and research institutions.

### 11.3 Key Risks
Federated Learning does not automatically eliminate privacy risk. Future FL-based SLE-DT systems must address:
- Model parameter leakage.
- Reconstruction attacks.
- Membership inference attacks.
- Sensitive attribute inference.
- Communication-channel vulnerabilities.
- Institutional governance complexity.

### 11.4 Candidate Future Capabilities
Future architecture may investigate:
- Federated learning.
- Secure aggregation.
- Differential privacy.
- Federated validation.
- Privacy auditing.
- Automated compliance verification.
- Federated model monitoring.

### 11.5 FL Design Requirement
If FL becomes part of a future SLE-DT phase, security, privacy, legal, governance, and clinical stakeholders must be involved from project initiation rather than after model development.

---

## 12. Cross-Disciplinary Stakeholder Requirements

### 12.1 MVP Stakeholders
The MVP should incorporate or seek feedback from:
- Bioinformatics experts.
- AI/ML researchers.
- Immunology experts.
- Rheumatology experts when available.

### 12.2 Future Clinical / Federated / Institutional Stakeholders
Future phases should include:
- Rheumatologists.
- Immunologists.
- Nephrologists.
- Dermatologists.
- Neurologists.
- Hematologists.
- Bioinformatics experts.
- AI/ML developers.
- Data scientists.
- Healthcare informatics experts.
- Federated solution architects.
- Security specialists.
- Privacy specialists.
- Legal/compliance experts.
- Governance stakeholders.

### 12.3 Stakeholder Principle
Healthcare AI and Federated Learning systems are socio-technical systems. Technical model development must be aligned with clinical, privacy, legal, governance, and security requirements.

---

## 13. Future AI Capability Roadmap

### 13.1 Single-Cell Extensions
- scRNA-seq integration.
- Automated cell-state annotation.
- Cell-state discovery.

### 13.2 Multi-Modal Patient Monitoring
Future phases may investigate:
- Clinical laboratory data.
- Patient-reported outcomes.
- Digital biomarkers.
- Wearable data.

### 13.3 Multi-Omics Digital Twin
Future phases may investigate:
- Genomics.
- Epigenomics.
- Proteomics.
- Cytokine profiling.
- Immune-cell phenotyping.

### 13.4 Federated / Privacy-Preserving AI
Future phases may investigate:
- Federated learning.
- Secure aggregation.
- Differential privacy.
- Privacy-preserving analytics.
- Agentic AI governance.

---

## 14. Validation and Verification Framework

### 14.1 Technical Validation
- Reproducibility.
- Stability.
- Cross-dataset consistency.
- Sensitivity analysis.
- Ranking robustness.

### 14.2 Biological Validation
Recover:
- Neutrophil pathways.
- Interferon pathways.
- B-cell signatures.
- Published hub genes.
- Literature-supported biomarkers.

### 14.3 Stratification Validation
Assess:
- Endotype stability.
- Cohort reproducibility.
- Within-endotype pathway consistency.
- Whether pathway rankings differ meaningfully across endotypes.

### 14.4 Security Validation (Future Phase)
Future implementations involving sensitive or institutional data should evaluate:
- Privacy leakage risk.
- Membership inference risk.
- Reconstruction attack risk.
- Sensitive attribute inference risk.
- Attack-surface exposure.
- Access-control effectiveness.
- Threat-model coverage.

### 14.5 Governance Validation (Future Phase)
Future implementations should evaluate:
- Compliance readiness.
- Documentation completeness.
- Explainability availability.
- Human-review processes.
- Approval workflows.
- Auditability.

### 14.6 Validation Principle
Validation must include more than performance metrics. For future clinical or federated versions, validation must include biological plausibility, software reproducibility, privacy risk, security risk, governance readiness, and stakeholder review.

---

## 15. Open Research Questions
Unanswered by currently reviewed literature:

1. Can deep learning outperform DEG-to-PPI workflows?
2. Which hub genes remain important under graph-learning approaches?
3. Can ML recover biologically meaningful genes removed by traditional thresholds?
4. How accurately can transcriptomics alone predict therapeutic targets?
5. Are public longitudinal SLE cohorts available?
6. How should production Digital Twins implement drift monitoring?
7. Can subtype-specific twins outperform generalized twins?
8. How should wearable-derived biomarkers be integrated?
9. Which public datasets contain both molecular and digital-health data?
10. What minimum biomarker set is necessary for a clinically useful lupus twin?
11. Has a fully customizable patient-specific SLE Digital Twin already been demonstrated?
12. Which healthcare DT category best aligns with lupus research goals?
13. Would an organ-specific lupus DT provide sufficient MVP value?
14. Should architecture evolve toward system-wide or organ-specific twins?
15. Which lupus target organ provides highest-value future organ-level twin?
16. Are existing lupus organ simulation platforms available?
17. Which biological, clinical, behavioral, and environmental variables are essential?
18. Are datasets from B-cell-targeting therapy studies publicly available?
19. Which SLE subtype is the most achievable MVP target?
20. Which sequencing and genome-analysis tools are most established in SLE research?
21. Can multi-omics AI models reliably predict individual treatment response?
22. Can digital-health platforms generate sufficiently standardized datasets for predictive AI?
23. What combination of clinical, laboratory, and patient-reported variables provides the strongest predictive value?
24. Should future ML grouping strategies rely primarily on biological markers, symptom clusters, severity, organ involvement, or treatment history?
25. How can privacy, security, and governance requirements be embedded directly into Lupus-DT workflows?
26. What validation criteria should be required before AI systems access or process sensitive healthcare data?
27. How can Federated Learning models be continuously audited for privacy leakage and security vulnerabilities?
28. What stakeholder approval workflows should be incorporated into future healthcare AI systems?
29. Which Federated Learning architecture is most suitable for a future multi-institution SLE Digital Twin?

---

## 16. Questions Partially Addressed by Current Literature
- SLE heterogeneity is a major modeling challenge.
- Patient stratification is necessary.
- Biological grouping appears more aligned with the current MVP than symptom-only grouping.
- Federated Learning may support future multi-institution collaboration without centralizing raw data.
- Federated Learning does not eliminate privacy risk because model updates and parameters can leak sensitive information.
- Security, privacy, legal, and governance expertise should be incorporated from the beginning of future healthcare AI or federated-learning projects.
- The Federated Learning review does **not** justify expanding the MVP; it informs future architecture and governance requirements.

---

## 17. Expected Thesis Contributions
- Explainable SLE Digital Twin architecture.
- Molecular-endotype-aware disease modeling.
- Immune-tolerance restoration framework.
- Heterogeneity-aware patient stratification.
- Validation-oriented healthcare Digital Twin methodology.
- Governance-aware design roadmap.
- Reproducible research platform.

---

## 18. Final MVP Recommendation
The recommended thesis MVP remains:

**A transcriptomics-first, molecular-endotype-aware, explainable SLE Digital Twin for immune-state modeling and immune-tolerance-restoration hypothesis generation.**

The MVP should not include Federated Learning, multi-omics integration, EHR integration, wearables, real-time monitoring, clinical decision support, or protected-data processing. These are retained as future roadmap items.

---

## 19. References (IEEE)
[1] Y. Zhao et al., “Identification of Biomarkers and Pathways in Systemic Lupus Erythematosus Through Integrated Bioinformatics Analysis,” 2021.

[2] GSE162828, Gene Expression Omnibus.

[3] GSE169080, Gene Expression Omnibus.

[4] STRING Database.

[5] Cytoscape Network Analysis Platform.

[6] M. E. Ritchie et al., “limma: Linear Models for Microarray and RNA-Seq Data Analysis.”

[7] “Artificial Intelligence, Biomarkers, and Precision Medicine in Autoimmune Inflammatory Rheumatic Diseases.”

[8] “Digital Twins and the Metaverse in Healthcare and Industry.”

[9] “Artificial Intelligence and Autoimmune Disease Research Trends,” 2025.

[10] “AI for Systemic Lupus Erythematosus Personalized Treatment.”

[11] “The Role of Health Information Technology in the Control and Management of Systemic Lupus Erythematosus.”

[12] “Federated Learning Security and Governance in Healthcare.”
